Minimal Residual Disease in Pancreatic Cancer – Our First Experiences

Česká verzia

Authors: Dušan Klos ; M. Loveček; P. Skalický ; J. Srovnal ^*; M. Kesselová ^*; L. Radová ^*; M. Hajdúch ^* ; Č. Neoral; R. Havlík
Authors place of work: I. chirurgická klinika FN a LF UP v Olomouci, přednosta: doc. MUDr. Čestmír Neoral, CSc. ; Laboratoř experimentální medicíny při Dětské klinice FN a LF UP v Olomouci vedoucí lékař: doc. MUDr. Marián Hajdúch, Ph. D. ^*
Published in the journal: Rozhl. Chir., 2010, roč. 89, č. 2, s. 135-139.
Category: Monothematic special - Original

Summary

Introduction:
Pancreatic cancer is one of the most aggressive malignity with the statistically shown an upward trend and a very poor prognosis. The causes we follow up in the local recurrence and in the early dissemination, either through hematogenic or lymphogenic way. Conventional methods are not able to capture these cells, just the modern molecular-biological methods make possible to fix the so-called minimal residual disease, that is the presence of isolated tumor cells in the patient’s body.

Material and Methods:
The study included 52 patients operated on the Clinic of Surgery I. in the University Hospital Olomouc for pancreatic cancer in different stages. QRT-PCR method was determined expression of hTERT, EGFR 1 and CEA both in peripheral blood, portal blood, bone marrow, peritoneal lavage and the tumor itself.

Results and Conclusion:
The results of this pilot study demonstrated a high sensitivity and specificity of the PCR method for detection of circulating tumor cells in patients with pancreatic cancer, extending this methodology, we are able to provide prognostic value of minimal residual disease and its significance for the indication of radical surgery for pancreatic cancer.

Key words:
pancreatic cancer – minimal residual disease – prognostic factors

Zdroje

1. Adam, Z., Vorlíček, J, Vaníček, J., et al. Diagnostické a léčebné postupy u maligních chorob. Praha, Grada Publishing, 2002.

2. Broll, R., Weschta, M., Windhoevel, U., et al. Prognostic significance of free gastrointestinal tumor cells in peritoneal lavage detected by immunocytochemistry and polymerase chain reaction. Langenbecks Arch. Surg., 2001; 386(4), 285–292.

3. Cress, R. D., et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control, 2006, 17, p. 403–409.

4. Imamura, M., et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery, 2004, 136, p. 1003–1011.

5. Graeven, U., et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer, 2006, 94, p. 1293–1299.

6. Koch, M., et al. Detection of Hematogenous Tumor Cell Dissemination Predicts Tumor Relapse in Patients Undergoing Surgical Resection of Colorectal Liver Metastases. Annals of Surgery, 2005; 241(2), 199–205

7. Niedergethmann, M., Rexin, M., Hildenbrand, R., et al. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am. J. Surg. Pathol., 2002; 26(12), 1578–1587.

8. Schuster, R., Max, N., Mann, B., et al. Quantitative real-time RT-PCR for detection of disseminated tumor cells in blood of patients with colorectal cancer using different mRNA markers. Int. J. Cancer, 2004; 108, 219–227.

9. Soeth, E., Grigoleit, U., Moellmann, B., et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J. Cancer Res. Clin. Oncol., 2005; 131(10), 669–676

10. Tamagawa, E., Ueda, M., Takahashi, S., et al. Pancreatic lymph nodal and plexus micrometastases detected by enriched polymerase chain reaction and nonradioisotopic single-strand conformation polymorphism analysis: a new predictive factor for recurrent pancreatic carcinoma. Clin. Cancer Res., 1997; 3(11), 2143–2149.

11. Taniguchi, T., Makino, M., Suzuki, K., Kaibara, N. Prognostic significance of reverse transcriptase-polymerase chain reaction measurement of carcinoembryonic antigen mRNA levels in tumor drainage blood and peripheral blood of patients with colorectal carcinoma. American Cancer Society, 2000; 89(5), 970–976.

12. Wolfrum, F., Vogel, I., Fandrich, F., et al. Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 2005; 390, 430-441